Form 4: BioCryst Director Milano Boosts Stake

BioCryst Pharmaceuticals Director Vincent Milano acquired 783 shares of common stock at $7.18 per share as part of his quarterly board retainer.

Summary

• Vincent Milano, a Director of BioCryst Pharmaceuticals Inc. (BCRX), acquired 783 shares of common stock.
• The transaction occurred on November 28, 2025, at a price of $7.18 per share.
• These shares were issued in lieu of 50% of his quarterly cash Board Member retainer, which is $11,250.
• Following this transaction, Mr. Milano directly beneficially owns 91,219 shares of BioCryst Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: Slightly positive as an insider is acquiring shares, indicating confidence, though it's part of a routine compensation plan rather than an open market purchase.

Positives

• A Director acquiring shares can signal confidence in the company's future prospects.
• The acquisition is part of a compensation structure, aligning management's interests with shareholders.

Negatives

• No specific negatives are indicated in this routine insider transaction report.

Risks

• This filing does not contain information regarding company-specific risks.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This routine insider transaction reflects a director's compensation structure and does not provide broader industry trend insights or competitive analysis.

Related Party Transactions

• The issuance of 783 shares of common stock to Director Vincent Milano in lieu of 50% of his quarterly cash Board Member retainer ($11,250) constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May view the director's stock acquisition as a positive signal of alignment with shareholder interests and confidence in the company's future.
• Management/Directors: The compensation structure, including stock-based retainers, aligns the financial interests of the director with the long-term performance of the company.

Next Steps

• This filing does not outline any specific future actions, events, or milestones for the company.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, Vincent Milano, Insider Trading, Form 4, Director Stock Acquisition, Common Stock, Board Retainer